» Articles » PMID: 34177592

Rifampicin Induces Gene, Protein, and Activity of P-Glycoprotein (ABCB1) in Human Precision-Cut Intestinal Slices

Overview
Journal Front Pharmacol
Date 2021 Jun 28
PMID 34177592
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

P-glycoprotein (ABCB1), an ATP-binding cassette efflux transporter, limits intestinal absorption of its substrates and is a common site of drug-drug interactions. Drug-mediated induction of intestinal ABCB1 is a clinically relevant phenomenon associated with significantly decreased drug bioavailability. Currently, there are no well-established human models for evaluating its induction, so drug regulatory authorities provide no recommendations for / testing drugs' ABCB1-inducing activity. Human precision-cut intestinal slices (hPCISs) contain cells in their natural environment and express physiological levels of nuclear factors required for ABCB1 induction. We found that hPCISs incubated in William's Medium E for 48 h maintained intact morphology, ATP content, and ABCB1 efflux activity. Here, we asked whether rifampicin (a model ligand of pregnane X receptor, PXR), at 30 μM, induces functional expression of in hPCISs over 24- and 48-h incubation (the time to allow complete induction to occur). Rifampicin significantly increased gene expression, protein levels, and efflux activity of ABCB1. Moreover, we described dynamic changes in ABCB1 transcript levels in hPCISs over 48 h incubation. We also observed that peaks of induction are achieved among donors at different times, and the extent of gene induction is proportional to PXR mRNA levels in the intestine. In conclusion, we showed that hPCISs incubated in conditions comparable to those used for inhibition studies can be used to evaluate drugs' ABCB1-inducing potency in the human intestine. Thus, hPCISs may be valuable experimental tools that can be prospectively used in complex experimental evaluation of drug-drug interactions.

Citing Articles

Effect of P-glycoprotein and Cotreatment with Sofosbuvir on the Intestinal Permeation of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Fumarate.

Huliciak M, Lhotska I, Kocova-Vlckova H, Halodova V, Dusek T, cecka F Pharm Res. 2023; 40(9):2109-2120.

PMID: 37594591 DOI: 10.1007/s11095-023-03581-2.


Knockout of ABC transporters by CRISPR/Cas9 contributes to reliable and accurate transporter substrate identification for drug discovery.

Feng D, Zhong G, Zuo Q, Wan Y, Xu W, He C Front Pharmacol. 2022; 13:1015940.

PMID: 36386127 PMC: 9649518. DOI: 10.3389/fphar.2022.1015940.


Precision cut intestinal slices, a novel model of acute food allergic reactions.

Hung L, Celik A, Yin X, Yu K, Berenjy A, Kothari A Allergy. 2022; 78(2):500-511.

PMID: 36377289 PMC: 10098956. DOI: 10.1111/all.15579.


Structural Design and Synthesis of Novel Cyclic Peptide Inhibitors Targeting Transcription.

Stephanie F, Saragih M, Tambunan U, Siahaan T Life (Basel). 2022; 12(9).

PMID: 36143370 PMC: 9506182. DOI: 10.3390/life12091333.


Effect of Genetic Variations in Drug-Metabolizing Enzymes and Drug Transporters on the Pharmacokinetics of Rifamycins: A Systematic Review.

Sileshi T, Mekonen G, Makonnen E, Aklillu E Pharmgenomics Pers Med. 2022; 15:561-571.

PMID: 35693129 PMC: 9176238. DOI: 10.2147/PGPM.S363058.


References
1.
Yamazaki S, Loi C, Kimoto E, Costales C, Varma M . Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein. Drug Metab Dispos. 2018; 46(8):1200-1211. DOI: 10.1124/dmd.118.080424. View

2.
Greiner B, Eichelbaum M, Fritz P, Kreichgauer H, von Richter O, Zundler J . The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest. 1999; 104(2):147-53. PMC: 408477. DOI: 10.1172/JCI6663. View

3.
Wang H, LeCluyse E . Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin Pharmacokinet. 2003; 42(15):1331-57. DOI: 10.2165/00003088-200342150-00003. View

4.
Wu J, Lin N, Li F, Zhang G, He S, Zhu Y . Induction of P-glycoprotein expression and activity by Aconitum alkaloids: Implication for clinical drug-drug interactions. Sci Rep. 2016; 6:25343. PMC: 4853792. DOI: 10.1038/srep25343. View

5.
Kalliokoski A, Niemi M . Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009; 158(3):693-705. PMC: 2765590. DOI: 10.1111/j.1476-5381.2009.00430.x. View